The Supreme Court petition filed against the pharmaceutical company Ranbaxy on Tuesday dismissed a public interest litigation the company sell bad quality and adulterated drugs on alleging demands action.
Justice a.k. Patnaik and justice advocate Manohar Lal Sharma bench of gogoi Ranjan on behalf of filing petition dismissed by saying that the petitioner company accused of making low quality and adulterated medicines to no subut or presenting content. the petitioner argued that the bench of the u.s. court order is based on.
But based on that hearing in India. the petitioner make low quality and adulterated medicines against the company could offer no content. However, the Court is exempted if it it Sharma in the future against the company to make low-quality medicines adulterated and met the new contents of the petition.
Sharma's petition in court by the base fines imposed by Ranbaxy sell adulterated drug demand action against. petitioner said company which sends us drugs and other countries, the same medications sold in India is found in that company by America adulterated and poor quality medicines, making it a penalty of $ 50 million on there for the company.
Justice a.k. Patnaik and justice advocate Manohar Lal Sharma bench of gogoi Ranjan on behalf of filing petition dismissed by saying that the petitioner company accused of making low quality and adulterated medicines to no subut or presenting content. the petitioner argued that the bench of the u.s. court order is based on.
But based on that hearing in India. the petitioner make low quality and adulterated medicines against the company could offer no content. However, the Court is exempted if it it Sharma in the future against the company to make low-quality medicines adulterated and met the new contents of the petition.
Sharma's petition in court by the base fines imposed by Ranbaxy sell adulterated drug demand action against. petitioner said company which sends us drugs and other countries, the same medications sold in India is found in that company by America adulterated and poor quality medicines, making it a penalty of $ 50 million on there for the company.
